HENAN SUNLAKE ENTERPRISE CORPORATION
Free supplier Enterprise Certification
- Free
supplier - 9th
years
Free supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: +86-371- 86259723
Tel: 17734809689
Tel: 17734809689
Tel: 86-371-86259723
Tel: 17734809689
Tel: 17734809689
Mobile: 17734809689
Tel: +86-371- 86259723
Fax: +86-371- 86259723
Province/state: HENAN
City: ZHENGZHOU
Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China
MaxCard:
Contact Suppliers
CAS NO.135046-48-9
| Clopidogrel hydrogen sulfate Basic information |
| Product Name: | Clopidogrel hydrogen sulfate |
| Synonyms: | PLAVIX;SR-25990C;CLOPIDOGREL BISULPHATE;CLOPIDOGREL HYDROGEN SULPHATE;CLOPIDOGREL SULPHATE;SR-25990C, Plavix, Methyl (+)-(S)-a-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)acetate, Hydrogen sulfate salt;Methyl (S)-alpha-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulfate;SR-25990, Methyl (2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate hydrogen sulfate |
| CAS: | 135046-48-9 |
| MF: | C16H16ClNO2S.H2O4S |
| MW: | 419.9 |
| EINECS: | |
| Product Categories: | Active Pharmaceutical Ingredients;chiral;Intermediates & Fine Chemicals;Pharmaceuticals;Purinergics P2 receptor |
| Mol File: | 135046-48-9.mol |
|
|
|
| Clopidogrel hydrogen sulfate Chemical Properties |
| mp | 184°C |
| storage temp. | 2-8°C |
| CAS DataBase Reference | 135046-48-9(CAS DataBase Reference) |
| Safety Information |
| Safety Statements | 22-24/25 |
| HazardClass | IRRITANT |
| Clopidogrel hydrogen sulfate Usage And Synthesis |
| Anti-platelet aggregation drug |
Thrombosis caused by arterial atheromatous plaque leads to acute thrombosis cardiovascular and cerebrovascular events. In this pathogenesis, platelets play a central role, which has been fully studied. Clopidogrel hydrogen sulfate is similar to ticlopidine, which is a new anti-platelet aggregation drug, successfully developed by French Sanofi - Synthelabo Fort for the prevention and treatment of heart, brain and other arterial circulation disorders caused by the high blood platelet aggregation, such as recent onset of stroke, myocardial infarction and patients diagnosed with peripheral arterial disease. Many countries have already used it, including United States, Europe and China. This product inhibited platelet activation by inhibiting adenosine diphosphate (ADP) pathway to inhibit platelet aggregation. Since clopidogrel hydrogen sulfate takes several days to achieve effective blood concentration, it does not apply to emergency treatment. Stop using 7 to 10 days, platelet function returned to normal state. The above information is edited by the chemicalbook of Kui Ming. |
| Chemical Properties | Colorless to light yellow liqui |
| Usage | Used as an antithrombotic |
| Usage | platelet aggregation inhibitors |
| Clopidogrel hydrogen sulfate Basic information |
| Product Name: | Clopidogrel hydrogen sulfate |
| Synonyms: | PLAVIX;SR-25990C;CLOPIDOGREL BISULPHATE;CLOPIDOGREL HYDROGEN SULPHATE;CLOPIDOGREL SULPHATE;SR-25990C, Plavix, Methyl (+)-(S)-a-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)acetate, Hydrogen sulfate salt;Methyl (S)-alpha-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulfate;SR-25990, Methyl (2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate hydrogen sulfate |
| CAS: | 135046-48-9 |
| MF: | C16H16ClNO2S.H2O4S |
| MW: | 419.9 |
| EINECS: | |
| Product Categories: | Active Pharmaceutical Ingredients;chiral;Intermediates & Fine Chemicals;Pharmaceuticals;Purinergics P2 receptor |
| Mol File: | 135046-48-9.mol |
|
|
|
| Clopidogrel hydrogen sulfate Chemical Properties |
| mp | 184°C |
| storage temp. | 2-8°C |
| CAS DataBase Reference | 135046-48-9(CAS DataBase Reference) |
| Safety Information |
| Safety Statements | 22-24/25 |
| HazardClass | IRRITANT |
| Clopidogrel hydrogen sulfate Usage And Synthesis |
| Anti-platelet aggregation drug |
Thrombosis caused by arterial atheromatous plaque leads to acute thrombosis cardiovascular and cerebrovascular events. In this pathogenesis, platelets play a central role, which has been fully studied. Clopidogrel hydrogen sulfate is similar to ticlopidine, which is a new anti-platelet aggregation drug, successfully developed by French Sanofi - Synthelabo Fort for the prevention and treatment of heart, brain and other arterial circulation disorders caused by the high blood platelet aggregation, such as recent onset of stroke, myocardial infarction and patients diagnosed with peripheral arterial disease. Many countries have already used it, including United States, Europe and China. This product inhibited platelet activation by inhibiting adenosine diphosphate (ADP) pathway to inhibit platelet aggregation. Since clopidogrel hydrogen sulfate takes several days to achieve effective blood concentration, it does not apply to emergency treatment. Stop using 7 to 10 days, platelet function returned to normal state. The above information is edited by the chemicalbook of Kui Ming. |
| Chemical Properties | Colorless to light yellow liqui |
| Usage | Used as an antithrombotic |
| Usage | platelet aggregation inhibitors |